Alot of negativity here so let me summize
chf : works reduces mortality - didn't meet primary plenty of dataGvhd: kicked back for another RCT
clbp : heaps of data primary endpoint was reached for those <5 years reported CLBP
the result? Even if we don't get approval, the treatment works and have a plethora of data to prove efficacy across all indications, also the current data will help model further trials around FDA approval (with better understanding of the current trials, endpoints reached, etc)
even though I believe we will get approval for at least ONE indication this year, that is all we really need.
shorters love this stock for a reason.
Bottom line: it works.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-376
-
- There are more pages in this discussion • 728 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
-0.025(1.86%) |
Mkt cap ! $1.507B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.35 | $1.31 | $2.699M | 2.040M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34995 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 10374 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |